Benitec Biopharma Inc. (BNTC)

NASDAQ: BNTC · IEX Real-Time Price · USD
0.372
+0.028 (8.24%)
At close: Sep 30, 2022 4:00 PM
0.370
-0.002 (-0.46%)
After-hours: Sep 30, 2022 7:13 PM EDT
8.24%
Market Cap 9.59M
Revenue (ttm) 73,000
Net Income (ttm) -18.21M
Shares Out 25.81M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,656
Open 0.370
Previous Close 0.343
Day's Range 0.330 - 0.384
52-Week Range 0.301 - 3.900
Beta 1.25
Analysts Buy
Price Target 10.20 (+2,644.1%)
Earnings Date Nov 14, 2022

About BNTC

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California. [Read more...]

Industry Biotechnology
Founded 1995
Employees 18
Stock Exchange NASDAQ
Ticker Symbol BNTC
Full Company Profile

Financial Performance

In 2022, BNTC's revenue was 73,000, an increase of 23.73% compared to the previous year's 59,000. Losses were -18.21 million, 31.2% more than in 2021.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BNTC stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 2,644.15% from the latest price.

Price Target
$10.2
(2,644.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel ...

2 weeks ago - GlobeNewsWire

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel ...

2 weeks ago - GlobeNewsWire

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel ...

1 month ago - GlobeNewsWire

Benitec Biopharma Releases Q3 2022 Financial Results

HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel ge...

4 months ago - GlobeNewsWire

Benitec Biopharma Discloses Q2 2022 Financial Results

HAYWARD, Calif., Feb. 14, 2022 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genet...

7 months ago - PRNewsWire

Benitec Biopharma Discloses Q1 2022 Financial Results

HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genet...

10 months ago - PRNewsWire

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

HAYWARD, Calif., Sept. 20, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

1 year ago - PRNewsWire

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the p...

1 year ago - PRNewsWire

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an o...

1 year ago - PRNewsWire

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an u...

1 year ago - PRNewsWire

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinica...

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Regulatory Update Highlights: Regarding European Regulatory Interactions: The BB-301 Pilot Dosing Study was viewed as an appropriate dose range finding stu...

1 year ago - PRNewsWire

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

1 year ago - PRNewsWire

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

1 year ago - PRNewsWire

Benitec BioPharma Shares Rally: Technical Levels To Watch

Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gain...

1 year ago - Benzinga

Why DLPN Stock And BNTC Stock Are Popping Off Today

Dolphin Entertainment Inc (NASDAQ: DLPN) shares are trading 150% higher after the company announced it launched a non-fungible token (NFT) creation and marketing division. Dolphin Entertainment produces...

Other symbols: DLPN
1 year ago - Benzinga

BNTC Stock: One Big Investor Has Benitec Biopharma Shares Going Bonkers

Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company. The post BNTC Stock: One Big Investor Has Benitec Biopharma Shar...

1 year ago - InvestorPlace

Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today

The shares of Benitec Biopharma Inc (NASDAQ: BNTC) are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday.  What Happened: Benitec shares had closed at $3.19 on Monday.

1 year ago - Benzinga

Benitec Biopharma's Gene Therapy For Rare Muscle Disorder Shows Encouraging Action In Animal Studies

Benitec Biopharma Inc (NASDAQ: BNTC) reports an interim analysis of the BB-301 Pilot Dosing study conducted in large animal subjects. BB-301 a genetic medicine directly injected into the pharyngeal musc...

1 year ago - Benzinga

Benitec Biopharma Announces 2020 Annual Stockholder Meeting

HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December 9, 2020 at...

1 year ago - PRNewsWire

Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Pur...

HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...

1 year ago - PRNewsWire

Benitec Biopharma Announces Pricing of $10.0 Million Public Offering

HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...

2 years ago - PRNewsWire

Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results

HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

2 years ago - PRNewsWire

Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference

HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.

2 years ago - PRNewsWire

Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study

HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the pro...

2 years ago - PRNewsWire

Penny Stocks to Buy Using Technical Analysis for March 2020

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Other symbols: SUPVTRIB
2 years ago - Investopedia